Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Lymphoma, B-Cell 1Disease Progression 1

Interventions

Rituximab 165Cyclophosphamide 163fludarabine phosphate 95Peripheral Blood Stem Cell Transplantation 88Filgrastim 72Etoposide 65Mycophenolic Acid 63Whole-Body Irradiation 62Cytarabine 59Cyclosporine 53Melphalan 52Tacrolimus 47Busulfan 43Radiotherapy 42Lenalidomide 42Bortezomib 40ibrutinib 39fludarabine 39Methotrexate 38Antilymphocyte Serum 38Carmustine 37Bendamustine Hydrochloride 35Vincristine 33Doxorubicin 32Dexamethasone 32Granulocyte Colony-Stimulating Factor 29Prednisone 26Cord Blood Stem Cell Transplantation 25venetoclax 22obinutuzumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Mantle-Cell × ublituximab × Clear all
NCT04783415 2024-12-02

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

City of Hope Medical Center

Phase 2 Active not recruiting
12 enrolled 8 charts
Lymphoid

Lymphoma, Mantle-Cell

NCT04692155 2023-09-28

CHOP U2

University of Alabama at Birmingham

Phase 1/2 Terminated
1 enrolled 5 charts
Lymphoid

Lymphoma, Mantle-Cell

NCT04635683 2022-09-30

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Withdrawn
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡